Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN TRIHYDRATE versus PIPERACILLIN TAZOBACTAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPICILLIN TRIHYDRATE versus PIPERACILLIN TAZOBACTAM.
AMPICILLIN TRIHYDRATE vs Piperacillin-Tazobactam
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activity.
Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Tazobactam is a beta-lactamase inhibitor that irreversibly inhibits beta-lactamases, preventing degradation of piperacillin.
250-500 mg PO q6h or 1-2 g IV/IM q4-6h; up to 12 g/day IV for severe infections.
3.375 g (piperacillin 3 g + tazobactam 0.375 g) IV every 6 hours; for nosocomial pneumonia, 4.5 g IV every 6 hours.
None Documented
None Documented
Terminal elimination half-life 1-1.8 hours; prolonged in renal impairment (up to 10-20 hours in anuria)
Piperacillin: ~0.7-1.2 hours (normal renal function); Tazobactam: ~0.9-1.3 hours. Prolonged in renal impairment (e.g., piperacillin half-life up to 3-6 hours in ESRD).
Renal: 75-90% unchanged; biliary: small amount; fecal: negligible
Piperacillin: ~68% renal excretion as unchanged drug, ~20% biliary/fecal. Tazobactam: ~80% renal excretion as unchanged drug, remainder as inactive metabolite.
Category A/B
Category A/B
Penicillin Antibiotic
Penicillin Antibiotic + Beta-Lactamase Inhibitor